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ABSTRACT 
INTRODUCTION: Bleeding diathesis is a very common occurrence in critically 
ill patients. The cause is usually multifactorial.  
AIMS and OBJECTIVES: To study about the incidence and the type of bleeding 
diathesis occurring in critically ill patients in the medical ICU.  
    To analyse and tabulate the common aetiologies of coagulopathy occurring in 
medical ICU patients. 
MATERIALS and METHODS: 50 patients admitted in medical ICU were 
selected irrespective of the presence of clinical bleeding and patient underwent the 
questionnaire and the following investigations namely prothrombin time (PT), 
activated partial thromboplastin time (aPTT), Platelet count, D dimer and 
Fibrinogen. 
 
1 Post graduate in Internal Medicine, Institute of Internal Medicine, RGGGH 
2 Professor of Medicine, Institute of Internal Medicine, RGGGH 
3 Professor of Hematology, Dept of Hematology, RGGGH 
  
RESULTS: Out of 50 patients 26 patients had coagulation abnormality. Any drop 
in platelet count or prolongation of PT, a PTT was considered coagulation 
abnormality. 23 patients out of 50 had thrombocytopenia with majority of patients 
having drop between 80,000 and 1 lakh cells per cu.mm. 3 patients had prolonged 
PT and 10 patients had prolonged aPTT. 1 Patient had DIC who was found to have 
thrombocytopenia, prolonged PT and aPTT. Sepsis was found to be the commonest 
etiology of coagulopathy and thrombocytopenia was the commonest coagulation 
abnormality in our study. Renal failure, liver failure and antithrombotic drugs were 
the other major causes.  
CONCLUSION: A rationale approach must be developed in treating critical care 
patients with abnormal coagulation. Too much aggressive transfusions can do more 
harm than good. A good clinical judgement along with updated knowledge is 
required to treat such patients. 
KEY WORDS: coagulopathy, disseminated intravascular coagulation (DIC), 
Prothrombin time (PT), activated partial Thromboplastin time (aPTT ), sepsis  
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INTRODUCTION 
Bleeding diathesis is common in critically ill patients. Patients may 
have clinical bleeding or only laboratory abnormalities in hemostatic tests. 
Thrombocytopenia, prolongation of PT or aPTT or both, low fibrinogen and 
increased fibrin degradation products are the expected abnormalities. The 
mortality is higher in ICU patients with bleeding tendency. These 
abnormalities can be independent predictors of survival1.  
Unnecessary transfusion at some clinical situations can do more harm 
to the critically ill patient. Use of anticoagulants to prevent deep venous 
thrombosis has also increased the risk of bleeding. There is also concern 
regarding the risk of bleeding when performing invasive procedures in these 
patients. 
Some causes of thrombocytopenia like thrombotic thrombocytopenic 
purpura should be recognized promptly as they can life threatening and also 
amenable to treatment if  identified early. 
There is a recent trend to follow restrictive strategy in blood 
transfusion which has shown that mortality is improved compared to liberal 
strategy2. Now there is an increase in awareness of harmful effects of massive 
transfusion. 
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Our study aims at determining the incidence and types of bleeding 
diathesis that commonly occur in our medical ICU. Patients are screened for 
bleeding diathesis by the following tests namely platelet count & peripheral 
smear, PT, aPTT, D-dimer and Fibrinogen irrespective of the presence of 
clinical bleeding. The incidence and the type of abnormality in the hemostatic 
tests and the underlying probable causes for the bleeding tendency are to be 
identified in this study. 
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AIMS & OBJECTIVES 
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AIMS & OBJECTIVES 
 
1. To study about the incidence and the type of bleeding diathesis 
occurring in critically ill patients in the medical ICU. 
2. To analyze and tabulate the common etiologies of coagulopathy 
occurring in medical ICU patients. 
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REVIEW OF LITERATURE 
 
NORMAL COAGULATION CASCADE :   
Coagulation of blood requires a cascade of reactions which ultimately 
converts fibrinogen  to fibrin. The clotting factors along with calcium and 
phospholipids are involved in fibrin formation. Two pathways namely 
intrinsic and extrinsic exist which leads to a final common pathway that 
results in clotting of blood3. 
In intrinsic system, high molecular weight kininogen and kallikrein 
activates factor XII which activates factor XI which further activates factor 
IX. Activated factor IX along with factor VIII forms a complex which 
activates factor X. Xa along with factor V, phospholipids and calcium 
converts prothrombin to thrombin.  
The extrinsic system involves activation of tissue thromboplastin factor 
which activates factor VII. VIIa activates IX and X finally joining the 
common pathway. The thrombin is a serine protease which catalyzes  
fibrinogen to fibrin4. Fibrin meshwork initially a loose network gets 
stabilized by factor XIII (Hageman factor) in the presence of calcium. 
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CHECKPOINTS IN COAGULATION CASCADE 
 There are checkpoints for coagulation cascade which will prevent 
excess clot formation and also inappropriate clot formation.  
 Tissue factor pathway inhibitor inhibits the extrinsic system of the 
coagulation cascade.  
 Tissue plasminogen factor activates plasminogen to plasmin5.  
 Plasmin lyses fibrin and fibrinogen and form Fibrin Degradation 
Products (FDP) that inhibit thrombin. 
 Antithrombin III is a protease that inhibits clotting factor activities 
thereby preventing clot formation. Thrombomodulin forms a complex 
with thrombin and activates Protein C. Protein C inactivates factor V 
and VIII thereby limiting clot formation6. 
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Fig 1: COAGULATION  CASCADE 
9 
 
 
 
 
 
 
 
 
 
 
10 
 
DISORDERS OF HEMOSTASIS IN CRITICALLY ILL 
MEDICAL ICU PATIENTS 
Coagulation abnormalities are very common in critically ill patients. 
History and clinical examination plays a major role in assessing such patients. 
Then comes the laboratory screening tests for hemostasis. All the lab values 
must be interpreted according to the clinical scenario.  
For eg. decompensated chronic liver disease and Disseminated 
intravascular coagulation can produce same pattern of coagulopathy yet the 
prognosis are very different. There are many causes for derangement of 
coagulation in critically ill patients and the underlying disorder may require 
specific treatment. Hence it is vital to identify the coagulation abnormality. 
The site of bleeding and its severity should be assessed first. The 
bleeding can be major, minor or fatal. The bleeding may follow a invasive 
procedure. Generally coagulation abnormalities develop after 48 hours of 
admission to ICU.  
Coagulopathies can be clinical or subclinical (only laboratory 
derangement without clinical bleeding). Aggressive transfusions can lead to 
its own serious consequences like TRALI (Transfusion related lung injury)7. 
Drug history of the ICU patient is very important as the patient may be 
getting multiple medications which can cause coagulation abnormalities  
11 
 
BASIC SCREENING TESTS : 
 The commonly used screening tests are PT, aPTT and the platelet 
count. D dimer and fibrinogen are measured if the clinical situation demands. 
aPTT:   
aPTT measures the time needed to generate fibrin from beginning of 
the intrinsic pathway. 
Technique:  
Citrated plasma, phospholipid and an activating agent like kaolin are 
added together and incubated at room temperature. Then calcium is added 
and the time necessary for clumping of kaolin is noted8. Normally it is less 
than 25 to 35 seconds. 
Abnormality: 
This test is abnormal in factor deficiencies that are involved in both 
intrinsic and common pathways of coagulation cascade. If the factors are less 
than 30 percentage then aPTT is prolonged.  
Mixing study: 
Mixing study is usually done in prolonged aPTT to distinguish from 
factor deficiency and presence of inhibitors. Patient sample is mixed with 
normal plasma in ratio of 1:1 and the test is repeated9. If the aPTT is 
12 
 
corrected, there is factor deficiency. If it is prolonged it suggests presence of 
inhibitor like lupus anticoagulants, paraproteins etc. 
Clinical significance:  
It’s a good screening test for factor deficiencies like factor VIII, IX, 
XII. These factors may be congenitally absent .Acquired causes include liver 
dysfunction and vitamin K deficiency. The presence of inhibitors like 
heparin, antithrombin III, lupus anticoagulant can prolong aPTT. Hence aPTT 
can be used to monitor heparin activity. 
PT: 
The time needed to generate fibrin after activation of extrinsic pathway 
and common pathway is measured by PT. 
Technique:  
Citrated plasma and thromboplastin are incubated at room temperature. 
Calcium is added and fibrin filaments are observed10. The normal value can 
vary from lab to lab. Generally it is between 12 to 15 seconds 
Clinical significance: 
Inherited deficiency of factor VII is rare. Acquired causes are usually 
the end stage liver disease and warfarin therapy. INR (International 
13 
 
Normalized Ratio) allows comparison between laboratories due to different 
thromboplastin usage. 
 
 
 
 
 
 
 
 
 
Fig 2 : COAGULATION  FACTOR 
ACTIVITY TESTED IN APTT IN RED 
AND PT IN GREEN. 
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Fig 3 : ABNORMAL COAGULATION 
PARAMETERS 
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Other tests : 
Thrombin time and Reptilase time measure fibrinogen conversion to 
fibrin and are prolonged when there is low fibrinogen as in inherited or 
acquired dysfibrinogenemia. The thrombin time is affected by heparin but not 
the reptilase time. Anti Xa assay is used to monitor heparin or low molecular 
weight heparin activity. 
Assessment of platelets quality and quantity: 
Platelet count : Automated cell counter provides the platelet count  
based on size. If there is clumping the machine may take it as an RBC. 
Always thrombocytopenia must be confirmed by examining the peripheral 
smear. Bleeding time is a crude technique which do not predict bleeding risk 
accurately11. Von willebrand factor assay and platelet aggregometry are 
further studies than can measure platelet dependent coagulation.  
Fibrinogen quantity: 
Fibrinogen plays an important role in coagulation cascade. 
Hyperfibrinogenemia is usually implicated in chronic inflammation and  
atherogenesis which may cause a thrombotic state12 . Normal value  lie 
between 150 to 450 mg/dl.  
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Hypofibrinogenemia occurs in DIC, liver disease, massive transfusion 
(dilutional coagulopathy) and inherited disease. Hyperfibrinogenemia occurs 
in pregnancy, acute phase reactant and female sex. 
D-Dimer : 
The latex particles are coated with mouse anti-human D-dimer 
monoclonal antibodies. Test samples containing D-dimers when mixed with 
the latex particle suspension make the particles agglutinate.  
The D-dimer levels are <0.5 ug/ml (expressed in FEU). The D-dimer 
level increases during pregnancy. It also rises with age ( >70 yr). Rheumatoid 
factor can give false positive D- dimer. Liver disease and DIC can have 
increased FDP. In clinical practice, parallel measurements of FDP and  
D-dimer are useful for more accurate estimation of hyperfibrinolytic states13.  
D dimer is also positive in conditions like deep venous thrombosis, 
sepsis and pulmonary embolism. Lipemia can also interfere with D dimer 
measurement. 
D dimer result should be interpreted along with PT, aPTT and platelet 
count. It  is one of the FDP that is specific for fibrinolysis. 0.5 microgram /ml 
of D dimer suggests 1 microgram / ml of fibrinogen is cleaved. 
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COMMON BLEEDING DIATHESIS IN  
MEDICAL ICU PATIENTS 
 
Thrombocytopenia : 
It is the most common coagulation abnormality that occurs in critically 
ill patients. Thrombocytopenia can be due to decreased production or 
increased destruction or sequestration. Incidence varies from 20 to 60 % 
depending upon the cut off value14.  
Platelets are the first line of defense when endothelium is breached. 
Highest incidence occurs in cases of sepsis. Usual cut off value is less than 
1,50,000 cells/cu.mm. But in critically ill patients thrombocytopenia can 
defined as count less than 1,00,000 cells/cu.mm. Etiology is usually 
multifactorial in critically ill patients15. 
First and foremost problem is spurious thrombocytopenia which should 
be ruled out before evaluating any patient with thrombocytopenia. EDTA 
antibodies can cause clumping and hence we may get a low count. Such 
sample should be repeated with citrate anticoagulant. Always confirm 
thrombocytopenia by looking at the peripheral smear.  
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ICU patients with thrombocytopenia have poor prognosis when 
compared with patients who have normal platelet counts. It is not necessary 
to treat all patients with thrombocytopenia. At the same time we should not 
miss serious conditions like heparin induced thrombocytopenia and 
thrombotic microangiopathy. Each condition needs different treatment 
modalities. 
Current studies state that if patient is hemostatically stable and has 
thrombocytopenia,  platelet transfusion can be withheld till the count drops 
less than 10,000 cells/cu.mm. If the patient is actively bleeding platelet count 
should be maintained above 50,000cells/cu.mm. For neurosurgical 
procedures count should be maintained above 1,00,000 cells/cu.mm.  
Immunological causes : 3 major causes are heparin induced 
thrombocytopenia, thrombotic microangiopathy and drug induced. 
 
   
HIT is a life threatening complication and the incidence is around 2 to 
3 %. Heparin forms complex with platelet factor 4 antibody which binds and 
activates platelets the
Thrombosis can be arterial, venous or both
days of heparin. Platelet count
discontinuation of heparin.
Patient who are supposed to re
platelet count. Incidence 
Standard assays for HIT are Serotonin Release Assay (SRA) and The Heparin 
Induced Platelet Activation Assay 
 
 
Immunological causes of thrombocytopenia in ICU
• Heparin induced thrombocytopenia
• Thrombotic microangiopathy
• Drug induced thromboctopenia
19 
reby causing thrombosis and thrombocytopenia. 
16
 .Platelets start to fall after five 
 starts to improve after 4 to 14 days of 
 
ceive heparin should have a baseline 
of HIT is higher in surgical than medical patients
(HIPA) 17. 
 
. 
 Diagnosis of HIT
diagnosis along with test positive for PF4 antibodies
 
 
• Pulmonary embolism
• Deep vein thrombosis
• Arterial thrombosis, acute coronary syndrome, Stroke 
• Peripheral arterial disease
• Adrenal haemorrhage
• Venous limb gangrene
Four factors helpful in diagnosis of HIT
• The degree of thrombocytopenia
• The timing of the platelet fall
• Presence of thrombosis
• Presence of other causes of thrombocytopenia 
20 
 is not straight forward. It is a clinic
. 
Manifestations of HIT 
 
o pathologic 
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When to suspect? 
If the platelet count falls by thirty percent or more and if the patient has 
new episodes of thrombosis or skin lesion between 4 and 14 days of  heparin  
administration HIT should be suspected and patient should be clinically 
assessed. 
 
 
 
 
4 ‘T’ assessment of HIT 
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Management of HIT:  
 Stop all heparin including low molecular weight and anti Xa. 
 Do not give platelet transfusion. 
 Use direct thrombin inhibitors like argatroban, lepirudin and add 
warfarin when platelet count is above 1lakh cells/cu.mm and also when 
adequate INR is obtained.  
 
 
 
  
Difference between type 1 and type 2 HIT 
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DRUG INDUCED THROMOCYTOPENIA 
The problem in diagnosing DITP is we often mistake it as immune 
thrombocytopenic purpura and also patient may not reveal that he/she is 
taking herbal medicines which would have been the actual etiology. 
Pathogenesis :  
DITP can cause life threatening bleeding tendency and many times it 
goes unrecognized. The drug dependent antibodies are formed only in the 
presence of sensitizing drugs. The drug binds platelet epitope on one side and 
drug dependent antibody on other side thus creating a sandwich. Therefore 
there is thrombocytopenia and hence the bleeding tendency. Moreover the 
platelets improve when the drug is glycoprotein 2b/3a or Ib18. 
DITP should be suspected when there is unusual occurrence of 
thrombocytopenia and also when a patient presents with recurrent 
thrombocytopenia often recovering well in between. Commonest mistake is 
diagnosing such people as immune thrombocytopenic purpura. 
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CRITERIA FOR DIAGNOSING DITP 
 Log on to the following website for DITP database 
www.ouhsc.edu/platelets
and are not available widely
circumstances. 
Management: 
 Stop the suspected drug that caused 
 If clinical bleeding occurs maintain platelet count more than fifty 
thousand cells/cu.mm
 Drug dependent antibodies can persist lifelong hence patient should 
avoid the drug indefinitely
 Corticosteroids should be stopped when DITP is confirm
DITP (common drugs
• Vancomycin, Rifampin
• Diclofenac
• Ranitidine 
• Abciximab, eptifibatide
• Carbamazepine
• Hydrochlrothiazide, methyl dopa
25 
 Drug dependent antibodies assay 
19
. Hence the diagnosis is based on clinical 
thrombocytopenia 
 
 
)
 
are not specific 
ed20. 
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As a physician we should report the experience to the FDA adverse 
event reporting system. It will also help to construct the database for the 
future. 
DITP should be suspected whenever there is an unusual occurrence of  
thrombocytopenia. In ICU it is even more difficult to diagnose as the etiology 
can be multifactorial. The management can be as simple as stopping the 
offending drug or beverage or herb. 
 
        THROMBOTIC MICROANGIOPATHIES (TMA) 
TMA is a group of disorders characterized by microvascular 
thrombosis. 
TMA includes acquired Thrombotic Thrombocytopenic purpura (TTP), 
congenital TTP, Hemolytic uremic syndrome and secondary thrombotic 
angiopathy. 
The first case was reported by Eli Moschowitz in  a sixteen  year old 
girl who presented with fever, anemia, albuminuria. She subsequently died 
and on post mortem her renal vessels showed hyaline thrombi. TMA 
preferably affects central nervous system and kidneys.  
 Hemolytic Uremic syndrome (HUS) was identified in children who 
developed renal failure following a diarrheal illness. But HUS patients 
recovered well and didn’t have the same course of  TTP
TTP pentad includes renal failure, microangiopathic hemolytic anemia, 
CNS involvement, fever and thrombocytopenia. TTP was largely described
females in the age group 10 to 39 years.
Pathogenesis: 
ADAMTS13 is a metalloprotease that is necessary to cleave Von 
Willebrand factor (VWF)
platelet aggregation and microvascular thrombosis
against ADAMTS13 in these patients prevent the depolymerase activity. 
Plasma exchange is known to supply 
treatment. 
SEVERE SEPSIS HAS FOU
 
 
myocardium pancreas
Thrombi in capillaries of organs in order
27 
21
. 
 
. Large VWF multimers promotes  intravascular 
22
. IgG autoantib
the enzyme which forms
ND TO DECREASE ADAMTS13 LEVELS 
kidney
adrenal 
gland
 of increasing severity
 in 
odies 
 the basis of  
 
 
brain
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Liver and lungs are relatively spared. Any organ can be involved. 
Incidence of TTP is common in age groups 30 to 50 years. Male to 
female ratio is 1:2. Obesity , heredity and African ancestry are risk factors for 
TTP. 
 
RENAL MICROVASCULATURE SHOWING 
INTRAVASCULAR THROMBI 
29 
 
 
 
Clinical presentation: 
Onset can be acute or insidious. CNS involvement includes headache, 
seizures, hemiparesis, lethargy, confusion, coma and other focal deficits.  
Bleeding tendencies include petechiae and purpura. Organ bleeding 
can occur.  
Acute renal failure occurs in 1/3rd of cases. 1/3rd will present with 
hemolytic anemia. Pancreatitis, heart failure and myocardial infarction can 
occur. 1/5th can have hepatosplenomegaly. 
Laboratory evaluation : 
Anemia of hemoglobin <5 g/dl is seen in 1/3rd of cases. LDH values 
are increased with usual value around 1200 IU/ml. serum haptoglobin is 
reduced. Direct coombs test is negative in most of the cases. Peripheral smear 
shows schistocytes  apart from thrombocytopenia. Platelet count is around 
20,000 cells/cu.mm in half the patients. ADAMTS13 activity can be 
measured in citrated plasma23. 
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Peripheral smear in TTP showing schistocytes 
  
 
 
 
 
• Congenital TTP (Upshaw
• TTP With acquired ADAMTS13 deficiency
• Secondary thrombotic microangiopathy
• Tissue transplant associated
• Cancer (erythroleukemia, metastatic carcinoma)
• Pregnancy associated (HELLP, eclampsia)
• Autoimmune disorders (SLE, APLA)
• Drugs (ticlopidine)
• Hemolytic uremic syndrome
31 
Differential diagnosis 
-Schulman Syndrome)
 
  
 
 
 
PLAN OF MANAGEMENT 
• Glucocorticoids
• Plasma exchange
• Plasma infusion
more than 12 hours
• After platelet count
and routine thromboprophylaxis
heparin)
• Continue until
>150,000/L, LDH
every other day for
• If response is durable,
32 
( prednisone 2 mg/kg per day)
1.5 volumes /day
15–30 mL/kg if plasma exchange
.
exceeds 50,000/L, give aspirin
(e.g., low-molecular
complete response for 3 days
normal), then decrease plasma
two more treatments and stop.
taper steroids
 
is delayed
80 mg/day
-weight
(platelets
exchange to
  
 
 
 
 
 
 
 
MONITORING IN TTP
• Monitoring:Neurologic status,Hemoglobin and 
platelet count ,
, LDH , Serum electrolytes, calcium, blood urea 
nitrogen (BUN), creatinine, ECG, cardiac 
enzymes
• Common complications: 
arrhythmias, infarction ,
bleeding or thrombosis ,Citrate toxicity 
(hypocalcemia, alkalosis)  and
reactions to plasma
33 
Blood film for schistocytes 
Cardiac 
Catheter-associated 
Minor allergic 
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SEPSIS RELATED COAGULOPATHY 
Sepsis related coagulopathy can vary from mild laboratory abnormality 
in the coagulation parameters to Disseminated Intravascular coagulation 
(DIC) 24. There is a complex interplay between hemostatic mechanisms that 
can either lead to a bleeding tendency or can also present with thrombosis. 
Development of  DIC is a poor outcome predictor of sepsis. 
How coagulation system is activated in DIC due to sepsis? 
The tissue factor dependent pathway is the trigger for activation of 
coagulation pathway . The pro inflammatory cytokines exaggerated by 
monocytes and macrophages  upregulate the tissue factor thus leading to 
activation of coagulation system. 
 
 
Figure showing activation of coagulation system in sepsis DIC 
  
Treatment for sepsis induced Coagulopathy
Fresh frozen plasma (FFP)
FFP is usually indicated in septic patients with active bleeding. 
role of prophylaxis25  
Factor concentrates and fibrinogen
It is usually indicated
specific coagulation factor deficiencies. No role of prophylaxis
 
 
Dysfunctional 
anticoagulant 
pathway 
• Lower levels of 
anti thrombin III
• Lower levels of 
protein C and S
35 
: 
 :  
:  
 in septic patients with active bleeding and 
Dysfunctional 
fibrinolytic system
• Release of 
plasminogen 
activator inhibitor 
type 1 causing a 
procoagulant 
situation
Platelet activation 
• Platelet are 
activated directly 
by endotoxins
• Activated platelets 
provide scaffold for 
the assembly of 
coagulation 
complexes
 
 No 
. 
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Platelets :  
Platelets should be transfused in patients with platelet count of less 
than fifty thousand cells/ cu.mm with active bleeding. If the patient is not 
bleeding then a threshold of upto 10 to 20 *103   can be allowed before 
transfusion. 
Vitamin K : 
Vitamin  K can be given parenterally 10 mg for 3 days in cases of  
relative deficiency. 
Heparin : 
If the patient has less risk of bleeding it can be used in purpura 
fulminans and as a prophylaxis for deep venous thrombosis (DVT). 
Protein C concentrate has been tried in pediatric population. Results 
awaited. 
Antithrombin:  
In case of severe deficiency antithrombin is given. It is not 
recommended for Prophylaxis. 
Management of sepsis related coagulopathy should  consider 
combination therapies targeting   inhibition of  Tissue Factor  activated 
coagulation in combined with restoration of anticoagulant pathways, as well 
as cytokines removal. 
37 
 
LIVER DISEASE AND COAGULOPATHY 
 
Decompensated chronic liver disease is usually thought as a 
hemorrhagic coagulopathy. These patients generally have abnormal 
coagulation tests. If  PT is prolonged more than 3 seconds from control 
certain procedures like liver biopsy or surgery cannot be performed. 
 
COAGULATION SYSTEM : 
Coagulation system in liver disease is complex. It is a dynamic process 
of hemostasis. There is decreased production of factors II, V, VI, IX, X, XI, 
XIII, fibrinogen, protein C, protein S and vitamin K. Hence there is a 
decrease in both pro coagulant and anticoagulant proteins. It is also a 
hyperfibrinolytic state. Increased  FDP and thrombocytopenia occur. Test 
results may be suggestive of a bleeding tendency. The hemostatic balance can 
be tipped off either way by precipitating factors like renal failure, infections 
etc26. 
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Figure showing the coagulation abnormalities in liver disease 
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THROMBOCYTOPENIA IN LIVER DISEASE: 
Thrombocytopenia can be due to myelosuppression (Hepatitis c virus  
infection, thrombopoeitin deficiency, ethanol direct toxicity, low grade DIC 
auto antibodies, folate deficiency), platelet sequestration. 
 
TEST FOR ASSESSING CAOGULOPATHY IN DCLD: 
INR liver , thromboelastogram , thrombin generation time are more 
accurate in assessing global hemostasis rather than the conventional tests. But 
still PT is used in Child Pugh scoring and INR is used in MELD scoring27. 
 
MANAGEMENT : 
10 mg parenteral vitamin K can given for 3 days for DCLD patients  
routinely. FFP should not be given routinely to DCLD patients who have 
abnormal coagulation parameters in the absence of clinical bleeding. 
Hazards of  unnecessary transfusion include Transfusion Related Lung 
Injury (TRALI), volume overload, increase in portal hypertension and risk of 
allergic reactions. 
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    Therapy                 Usage  Comment  
RBC transfusion Bleeding patients Target Hb 7 to 8g/dl 
Vitamin K Every patient May not be useful if 
patient has no 
deficiency 
Fresh frozen plasma doubtful in bleeding 
patients 
May be used in 
bleeding patients 
when volume 
expansion is not an 
issue 
Platelets Count less than 50,000 Limited data 
Cryoprecipitate In patients who bleed Limited data 
 
 
Prothrombin complex 
concentrate 
In patients who bleed Limited data 
Desmopressin In patients who bleed Efficacy unproved 
Aprotinin, tranexamic 
acid, and epsilon amino 
caprioic acid 
Patients with 
hypofibrinogenemia  
Fibrinogen less than 
100mg/dL 
Can induce 
thrombosis 
Recombinant factor VII In placing ICP devices, 
bleeding after surgery, 
massive variceal bleed 
Can induce 
thrombosis 
 
 
Table showing management options in coagulopathy  
due to liver disease 
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To conclude , hemostasis in patients with DCLD is a complex issue 
with opposing forces which are in dynamic equilibrium and are affected by 
external factors like infection and renal failure. Currently, available tests for 
hemostasis have a poor predictability for bleeding or thrombosis in patients 
with DCLD. New tests like Thromboelastogram , thrombin tests may give a 
better idea but need prospective studies. But still conventional tests like PT, 
INR are in use for evaluating the severity of the disease28. 
The role of specific interventions like antifibrinolytics, platelet 
transfusion and recombinant factors, anticoagulant usage need to be defined 
clearly. 
Note :  The INR liver is PT calibrated using plasma from patients with 
DCLD instead of vitamin K antagonists like acitrom  and may resolve 
variability of INR in these patients. 
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COAGULOPATHY IN RENAL DISEASE 
Usual clinical manifestations would be epistaxis, petechiae and 
bleeding from local site. 
 
Peritoneal dialysis, conjugated estrogen, desmopressin, erythropoietin 
are all useful for improving bleeding time  
 
 
 
 
platelet 
dysfunction 
in uremia 
altered 
platelet 
granules
uremic 
toxins
decrease in 
thromboxane
dysfunctional 
VWF
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UREMIA AND ITS EFFECTS ON PLATELETS 
44 
 
 
 
In anemia when the hematocrit falls below 30 there is loss of laminar 
flow (where the RBC will be in central portion and platelets along the 
endothelium normally). 
Now the platelets are no longer easily available to the endothelium for 
formation of platelet plug. Hence there is prolongation of bleeding time. 
Estrogens decrease synthesis of L-arginine, which is a precursor of 
NO, resulting in decreased production of cyclic GMP as well as an increased 
production of thromboxane A2, and ADP which is crucial for the formation 
of platelet plugs. 
They may also decrease protein S and antithrombin and enhance factor 
VII. 
The dose of conjugated estrogens necessary to improve bleeding time 
and clinical bleeding in uremia is 0.6 mg/kg i.v during 30 minutes O.D for 5  
consecutive days 
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COMMON ANTITHROMBOTIC DRUGS USED IN ICU 
ASPIRIN:  
It is an antiplatelet drug that irreversibly inhibit cyclooxygenase 
enzyme. Its effect can persist up to  days even though the half life is 20 mins. 
Platelet transfusion is the procedure for immediate reversal 29. 
CLOPIDOGREL:  
 It is a P2Y12 antagonist that is metabolized by the liver and has a half 
life of six to fifteen hours. Platelet transfusion is the procedure for immediate 
reversal. 
UNFRACTIONATED HEPARIN: 
 It has indirect anti Xa and anti IIa effect. It also increases the action of 
antithrombin by a factor of 10,000. Its half life is forty five to ninety minutes. 
Protamine at a dose of 1 mg neutralizes 100 units of unfractionated heparin. 
LOW MOLECULAR WEIGHT HEPARIN: 
Action is same as unfractionated heparin but mainly Xa effect. It is 
cleared by the kidneys and half life is around 4 hours. Protamine neutralizes 
sixty percent of its effect. In case of life threatening bleeding use recombinant 
factor VII. 
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DANAPAROID: 
A  heparinoid with a ratio of anti Xa to anti IIa of >20. It is excreted by 
the kidneys. No specific antidote available . Half life is 24 hours. 
FONDAPARINUX: 
It is a synthetic pentasaccharide with indirect anti Xa effect. It is 
eliminated by kidneys and has a half life of 17 to 20 hours. No specific 
antidote available 
BIVALIRUDIN: 
It has direct antithrombin effect and commonly used in interventional 
cardiac procedures. It is short acting (24 min). No specific antidote available. 
ARGATROBAN:  
 It is a direct thrombin inhibitor which has a half life of 44 min and is 
metabolized by the liver.  No specific antidote available. 
VITAMIN K ANTAGONISTS (VKA): 
It reduces functional levels of vit K dependent clotting factors 
(2,7,9,10). It is metabolized by the liver. Antidotes are vit K parenteral and 
prothrombin complex concentrates. If prothrombin complex concentrates are 
not available use FFP. 
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DABIGATRAN:  
 It is a direct thrombin inhibitor and excreted by the kidneys. Half life is 
around 13 hours. No specific antidote available. In case of life threatening 
bleeding use recombinant factor VII. 
RIVAROXABAN, APIXABAN, EDOXABAN: 
 These are direct anti Xa inhibitors. Undergoes both hepatic and renal 
metabolism. No specific antidote available. 
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DISSEMINATED INTRAVASCULAR COAGULATION  
(DIC) 
Definition : 
Disseminated intravascular coagulation (DIC) is a clinic pathologic 
syndrome in which extensive intravascular coagulation occurs as a result of  
exposure or production of procoagulants inadequately balanced by natural 
anticoagulant mechanisms and intrinsic fibrinolysis. 
          Disturbance of the endothelium in the microcirculation along with 
inflammatory cells and release of inflammatory cytokines play a key role in  
the mechanism of DIC. 
Diffuse multiple organ bleeding, hemorrhagic necrosis, and thrombus 
in large and medium blood vessels and  microthrombi in small blood vessels 
are common findings at post mortem. 
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Figure showing activation of coagulation in DIC 
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Clinical conditions that complicate DIC 
• Malignancy
• Trauma
• Sepsis
• Obstetric complications (Abruptio placentae, HELLP 
syndrome)
• Transfusion reactions 
50 
ASSOCIATED WITH DIC
 Hemorrhagic necrosis
Coma, convulsions
Bleeding, intestinal ischemia
ARDS 
Hepatic failure, jaundice
AKI, acute cortical necrosis
Shock, infarction
Purpura, bleeding from injury 
sites 
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DIC SCORING SYSTEM 
 
  
LABORATORY FINDINGS IN DIC 
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Purpura Fulminans: 
Purpura fulminans is a severe, lethal form of DIC in which vast areas 
of the skin over the extremities and buttocks undergo hemorrhagic necrosis. 
The disease affects children predominantly and occasionally adults30.  
Diffuse microthrombi in small blood vessels and necrosis are present 
in biopsies of skin lesions. Onset can be within 2 to 4 weeks of a mild 
infection like scarlet fever, or rubella, or can occur during an acute infection 
in patients with acquired or hereditary thrombophilias affecting the protein C 
pathway.  
Patients affected by purpura fulminans are sick with fever, 
hypotension, and bleeding  from multiple sites and they usually have typical 
laboratory abnormalities of DIC. 
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MANAGEMENT OF DIC 
First and foremost thing in DIC is to treat underlying disorder. For 
example in sepsis antibiotics must be directed against the organisms 
responsible for sepsis Intensive support of vital functions is needed.  
Adequate Volume replacement and correction of low perfusion state,  
acidosis, and oxygenation may improve blood flow and oxygen delivery to 
the circulation.  
Organ support measures like hemodialysis in AKI and ventilator for 
respiratory failure are necessary if the patient develops multi organ failure. 
Vitals, renal and liver function must be monitored periodically. 
 
BLOOD COMPONENT THERAPY: 
The past concept that transfusion can worsen DIC is outdated. Now it 
is rational to give platelet transfusion, cryoprecipitate, Fresh Frozen plasma 
or prothrombin complex concentrate in a patient who is actively bleeding.  
Role of heparin in DIC is still controversial. Anti fibrinolytics like 
tranexamic acid has increased the risk of thrombosis and hence they are not 
recommended routinely 31. 
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Antithrombin III has been beneficial in small clinical trials but not  yet 
approved for usage. Recombinant Activated Protein C (APC)  has been 
licensed in many  countries for its usage in sepsis with organ failure. Most 
frequent side effect of APC is bleeding. 
 
MEDICAL MANAGEMENT OF BLEEDING IN THE   
CRITICALLY ILL  
Points to note: 
1. Dilutional anemia can occur if there is a massive transfusion . Hence it 
is better to follow restrictive strategy. 
2. Hypothermia impairs coagulation. There is a 33% reduction in  clotting 
factor activity at temperatures less than 33 degree celcius. 
3. Acidemia can reduce activity of factor II and VII as well as depress  
platelet function 
 
DESMOPRESSIN: 
Synthetic analogue of anti diuretic hormone. It releases VWF from 
endothelial storage sites. Dosage is 0.3 microgram/kg. It lacks  
vasoconstrictive activity32. Transient headache, flushing can occur. 
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FRESH FROZEN PLASMA: 
FFP is prepared by centrifugation method and then treated with a 
solvent to inactivate lipid coated viruses like hepatitis C, B. Average  volume 
of FFP 1 unit is equal to 200 ml. Risk  of TRALI is less with solvent treated 
FFP 
FFP is used to replace clotting factor deficiencies either single or 
multiple factors. FFP is also used in TTP for plasma exchange. Clotting 
factors must reduce by 30% to cause clinical bleeding. Four units of  FFP will 
increase the clotting factors by 10 %. 
CRYOPRECIPITATE: 
The following components are the major constituents in cryoprecipitate 
1. Factors VIII and XIII 
2. VWF 
3. Fibronectin 
4. Fibrinogen 
1 unit contains 70 IU/ml of factor VIII and 140 mf of fibrinogen. 
Recommended if the bleeding is due to hypofibrinogenemia and for  
hemophilia if factor VIII not available. ABO compatibility is not  essential. 
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FIBRINOGEN: 
Minimum fibrinogen level  required for hemostasis is 0.75 g per litre. 
Commercial fibrinogen preparations are not available in most of the  
countries. 
CRYOSUPERNATANT: 
Supernatant plasma separated during cryoprecipitate preparation. It has 
VWF, factor XIII and fibronection. It is low in fibrinogen and factor VIII. 
PLATELETS:  
Platelet transfusions are indicated to maintain desired platelet count  
according to the clinical setting. For e.g CNS surgeries require minimum 
platelet count of 1 lakh cell/cu.mm. 
One single donor platelet is equal to 4 to 6 random pooled donors. 
Platelet concentrates are slightly acidic and volume varies from 150-300 ml.  
Platelets are contraindicated in TTP and HIT. One unit of platelet 
raises the count by 20,000 cells. Splenic sequestration can produce different 
results. It is usually given over a period of 30 mins using a standard 
intravenous set. 
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ANTIFIBRINOLYTICS: 
They  act by inhibiting serine proteases like plasmin by reducing 
conversion of plasminogen to plasmin, preventing plasmin binding, and 
displacing it from the developing clot. 
Aprotinin is more effective when used prophylactically and  can 
decrease the bloodloss during major surgeries associated  with massive blood 
loss ,especially in cardiothoracic  surgeries. 
Aprotinin is given at dose of 14 mg and is quickly excreted. Therefore 
continuous infusion should be maintained.  
 
LYSINE ANALOGUES:  
Amino caproic acid and tranexamic acid are the lysine  analogues that 
bind to plasminogen as it has five binding sites. 
Aminocaproic acid half life is short and given in dose of 5 g i.v loading 
over 1 hour and then 1 to 2 g every hour till bleeding stops. There is lesser 
risk of anaphylaxis. 
Tranexamic acid at a dose of 10 mg /kg inhibits fibrinolysis (better 
than aminocaproic acid) and has been used to reduce bleeding after 
tonsillectomy, prostate surgery and severe menorrhagia. 
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COAGULATION FACTOR CONCENTRATES 
Coagulation factor concentrates include Factor XIII, and Factor VIIa,   
prothrombin complexes. They are commonly indicated in trauma, liver 
disease, and any oral anticoagulant toxicity.  
They provide a rapid and easy method of improving Coagulation 
stability without the hazard of FFP transfusion, volume load, or infections. At 
a dose of 30 IU/ kg  i.v prothrombin complex concentrate reversed 
coagulation deficiencies completely33. 
Recombinant Factor VIIa is approved for the management of 
Coagulopathy  with inhibitors to factors VIII or IX, but also effective in 
patients with injury, thrombocytopenia, and oral anticoagulants  overdose. 
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MATERIALS AND METHODS 
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MATERIALS AND METHODS 
The study was conducted in Intensive Medical Care Unit (IMCU),   
Institute of Internal Medicine, Madras Medical College, Rajiv Gandhi 
Government General Hospital, Chennai-600003 during the period  between 
March 2014 and August  2014. 
The laboratory work was done with the help of the hematology 
department , MMC & RGGGH . 
50 patients were studied who were admitted in IMCU , IIM, RGGGH . 
a patient is said to have a coagulopathy if he/she has either one or 
combination of following abnormalities 
1. Thrombocytopenia (less than 1 lakh cells/cu.mm) 
2. Prolonged PT 
3. Prolonged aPTT          
INCLUSION CRITERIA: 
1. Patients with any medical illness admitted to ICU who do not have   
primary hematological disease at the time of admission. 
2. Patient should have been in ICU for a minimum of 48 hours. 
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EXCLUSION CRITERIA: 
1. Patients who have already known hematological disease  
2. Surgical ICU patients (e.g trauma patients) 
Patients have their history taken according to the Questionnaire and 
subjected to clinical examination and investigations. 
The following tests of hemostasis are done only once. 
 1) Platelet count and peripheral smear  
 2) PT (Prothrombin time) 
 3) aPTT (activated Partial Thromboplastin Time) 
 4) Fibrinogen   
5) D-dimer 
The results were analyzed and  tabulated  with the help of  EPI INFO 
statistical software. 
CONSENT: 
Written and informed consent were obtained from all the participants 
in feasible cases or their attenders 
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ETHICAL COMMITTEE APPROVAL:  
The study was approved by INSTITUTE OF ETHICAL COMMITTEE 
of MADRAS MEDICAL COLLEGE. 
CONFLICT OF INTEREST :  None  
SPONSORSHIP   :  None 
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OBSERVATION AND RESULTS 
The results of the study  were tabulated and analyzed. The coagulation 
parameters and their underlying etiology were analyzed . D- dimer and 
fibrinogen were considered together with other basic parameters like PT, 
aPTT and platelet count. 
D-dimer can be elevated in venous thromboembolism, pregnancy, 
advanced age, inflammatory conditions, liver disease, malignancy and recent 
surgery. It is a sensitive but not a specific parameter to consider it separately. 
Similarly  Fibrinogen is also not a specific marker. It can be elevated in 
acute myocardial infarction, sepsis, pregnancy, inflammatory disorders and 
peripheral vascular disease. Low levels of fibrinogen is seen in conditions 
like end stage liver disease, DIC and afibrinogenemia. 
The commonest laboratory abnormality in hemostasis and common 
critical care diseases that cause deranged coagulation parameters were 
studied. 
The following variable were included in the analysis; 
Age, sex,  serum creatinine, serum total bilirubin, presence of clinical 
bleeding, site of bleeding, anticoagulant usage, PT, aPTT, platelet count, 
peripheral smear,  D-dimer and fibrinogen levels . 
 D- dimer and fibrinogen abnormalities cannot be interpreted 
independently. PT and aPTT must be considered together to confirm 
hemostatic abnormality.
 
    
The highest number of critical care patients (21) were in the age group 
13 to 39 years. There were 18 and 11 patients in the age groups 40 
-89 years respectively. Total number of patients studied were 50. All the 
patients were admitted in medic
Fig 1: distribution of study population age wise.
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Table 1: age wise distribution of study population
 
Fig 2: sex wise distribution of study population
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 Majority of the patients in our study were males (31). Females were 19 
in number. 
Sex  
Male 
Female  
 
Table 2: S
 
Fig 3: Distribution of patients with coagulation abnormalities in 
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Table 3: Distribution of patients with coagulation abnormalities  
in each age group 
 
Coagulation abnormality is considered as either decrease in platelet  
count or increase in PT or aPTT in our study. D-dimer and fibrinogen can be 
elevated non specifically in sepsis and other critical conditions. 
Majority of  hemostatic abnormalities occurred in the majority group 
i.e 13- 39 years whereas least % of hemostatic abnormality were observed  
in elderly age group. 
 
 
Age (in years) 
Total No. of 
patients in each 
age group 
No of patients 
with coagulation 
abnormality 
Percentage (%) 
13-39 21 13 62 
40-59 18 9 50 
60-89 11 4 36 
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Renal failure is also an important cause of bleeding diathesis in ICU. It 
can cause platelet dysfunction in the presence of normal platelet count. 
Platelet dysfunction due to uremic toxins lead to prolonged bleeding 
time.  
Heparin is also used in CKD patients during hemnodialysis. 
Peritoneal dialysis,estrogen , desmopressin have found to improve 
platelet function. 
 
Fig 4: shows number of patients with renal failure in study population  
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Table 4: showing the number of patients with renal failure  
in our study population 
 
Serum creatinine of more than 1.5 was considered as renal failure for 
the study purpose. 30 percent of ICU patients in our study had renal failure. 
The bleeding diathesis can be multifactorial in ICU patients. Uremia is 
one of the important contributor of the coagulopathy seen in ICU patients. 
 
 
Renal failure No. of patients (n=50) 
presence of renal failure 15 
absence of renal failure 35 
  
 
Figure   5: showing the number of patients with renal failure with
without coagulopathy in our study population
 
Out of 15 patients with renal failure 7 people had abnormal coagulation  
parameters. Uremia can cause abnormal platelet function without a reduction 
in platelet count. 
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Coagulopathy Renal failure patients (n=15) 
presence of Coagulopathy 7 
absence of Coagulopathy 8 
 
Table  5: showing the number of patients with renal failure with and 
without coagulopathy in our study population 
 
 
Elevated liver parameters No. of patients (n=50) 
presence of Elevated liver parameters 7 
Normal LFT 43 
 
Table 6: showing the number of patients with elevated liver parameters 
in our study population 
 
 Figure 6: showing the number of patients with elevated liver 
Out of 50 study patients 43 patients had normal liver function test 
parameters and 7 had deranged LFT. Hemostasis in liver disease is complex 
as there is reduction in both pro coagulant and anticoagulant proteins. So 
there is a dynamic balance.
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Table 7: showing all patients with deranged LFT had coagulopathy
Figure 7: showing all patients with deranged LFT had coagulopathy
The coagulation abnormality was seen in almost all patients with 
deranged LFT. Commonest bleeding was 
hemetemesis and oral cavity bleed in our study.
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Anemia No of patients 
presence of anemia 36 
absence of anemia 14 
 
Table 8 : shows the prevalence of anemia in our study population 
Anemia was based on peripheral smear which showed microcytic 
hypochromic anemia in 36 out of 50 patient. Remaining 14 patients showed 
normal study. 
 
Figure 8 : shows the prevalence of anemia in our study population 
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Anemia also plays its role in bleeding diathesis particularly in renal 
failure. When Hematocrit falls less than 30 there is loss of axial red blood cell 
flow and platelets are not pushed to endothelial side which can prolong 
bleeding time. 
Thrombocytopenia No of patients 
presence 23 
absence 27 
 
Table 9 : shows the prevalence of thrombocytopenia in our study 
population 
 
 
Figure  9 : shows the prevalence of thrombocytopenia in our  
study population 
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Thrombocytopenia is the most common coagulation abnormality in 
ICU patients. In our study  46 % of study population was found to have 
thrombocytopenia. In critically ill patients cut off value of 1,00,000 cells / 
cu.mm can be used instead of the usual 1,50,000 as there is no significant  
bleeding tendency to occur between these cutoff values. 
 
platelet count (cells/cu.mm) No. of patients 
1 lakh to 80,000 13 
79,000 to 50,000 6 
49,000 to 20,000 3 
<20,000 1 
 
 
Table  10 : shows the severity of thrombocytopenia in our study 
population 
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Figure 10 : shows the severity of thrombocytopenia in our study 
population 
 
Majority of patients (13) had platelet counts between 80,000 and 1 lakh 
which may not cause major bleeding per se. 3 patients had platelet count 
between 20,000 and 49,000 cells/cu.mm. Only one patient had platelet count 
less than 20,000 cells/cu.mm. 
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Clinical bleeding No. of patients with coagulopathy 
presence 14 
absence 12 
 
Table  10 : shows the occurrence of clinical bleeding  in our study 
population who had abnormal coagulation 
 
Figure 10 : Shows the occurrence of clinical bleeding  in our study 
population who had abnormal coagulation 
More than half of the patients who had abnormal coagulation 
parameters had clinical bleeding. 
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Table  11 : shows the occurrence of site of clinical bleeding  in our study 
population who had abnormal coagulation
 
Figure 11 : shows the occurrence of site of clinical bleeding  in our study 
population who had abnormal coagulation
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Melena was the most common bleeding manifestation followed by skin 
bleed. Not even a single patient in our study had life threatening bleeding 
episode. 
 
Table  12 : shows the usage of antithrombotics in our study population 
 
Figure   12 : shows the usage of antithrombotics in our study population  
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Table 13 : shows the type of antithrombotics used in our study 
 
Figure  13 : shows the type of antithrombotics used in 
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Table  14 : shows clinical bleeding in our study population who was on 
antithrombotics for some indications 
 
 
Figure 14 : shows clinical bleeding in our study population who  
was on antithrombotics for some indications 
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Antithrombotic are commonly used in ICU patients. The problem with 
these drugs arises when patien
procedure is planned. In our study six patients was on antithrombotics.  Out 
of six, four patients developed clinical bleeding. Heparin was the frequent 
drug that was used. 
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Table 15 : study population and PT INR prolongation
Figure 15 : study population and PT INR prolongation
Out of fifty patients studied 3 patients had PT prolongation.
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Table 16 : study 
 
Figure 16 : study population and aPTT prolongation
Out of fifty patients studied 10 patients had aPTT prolongation.
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Table 17 : study population and fibrinogen 
Figure 17 : study population and fibrinogen abnormality
 
None of the study patient had hypofibrinogenemia. 17 patients had 
hyperfibrinogenemia i.e fibrinogen levels >450 mg/dl. 
Hyperfibrinogenemia can be elevated in sepsis, atherosclerosis, 
coronary artery diseases and other  chronic inflammatory states. Hence it is 
always interpreted along with other coagulation tests.
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Table 18: study population and combined PT and aPTT abnormality
 
Figure 18: study population and combined PT and aPTT abnormality
Out of fifty patients only 2 patients had combined PT and aPTT 
prolongation 
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Table 19 : study population and D dimer positivity
 
Figure 19 : study population and D dimer positivity
Almost majority of patients (43) had D dimer positivity. Like 
fibrinogen D dimer results should always be interpreted along with other 
coagulation tests. D dimer is sensitive but not a specific marker for 
pulmonary embolism. It can be elevated in inflammatory conditions,        
liver disease and even in pregnancy.
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Table 20  showing patients with thrombocytopenia + PT and aPTT 
prolongation + d dimer positivity 
 
 
Table 20  showing patients with thrombocytopenia + PT and aPTT 
prolongation + d dimer positivity 
Only one patient had thrombocytopenia + PT and aPTT prolongation + 
d dimer positivity. That patient had developed DIC secondary to Sepsis 
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Table 21 showing the common causes of coagulopathy in our study 
population. 
 
 
 
Etiology of coagulpathy No. of patients 
DIC 1 
Sepsis 8 
Liver disease  4 
Renal disease 3 
Antithrombotic drug induced 4 
Immunological thrombocytopenia 0 
Others  6 
  
 
 
Figure 21 showing the common causes of coagulopathy in our study 
 
As in any other ICU patients sepsis ranks first 
followed by liver failure and antithrombotic drugs and renal failure. We did 
not have any case of immune mediated thrombocytopenia
 
3
4
0 6
Etiology of coagulpathy 
91 
population. 
in causing coagulopathy 
 
1 8
4
DIC
Sepsis
liver disease 
renal disease
antithrombotic drug induced
immunological 
thrombocytopenia
others 
 
92 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
93 
 
 
 
DISCUSSION 
    
Coagulopathy is common in critically ill patients. The spectrum varies 
from mild abnormality in coagulation parameters to life threatening bleeding. 
The coagulopathy in critical care patients is usually multifactorial.  
 
With the latest update on management of coagulopathies, recently  
guidelines have arrived when to correct a coagulation abnormality which was 
lacking previous years.  
 
The main aim of the study was to study the incidence and type of 
coagulation abnormality  that occurs in critically ill patients in the ICU set up 
in RGGGH. We also had a secondary objective to study the common 
etiologies behind these coagulopathies in ICU patients. 
 
Almost half the patients had coagulopathy  in our study . The incidence 
was higher in the younger age group as they form the majority. Nearly 50 % 
of renal failure patients in our study had coagulopathy. Almost all patients 
with liver failure in our study had bleeding diathesis. 
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More than 50 % of patients with coagulopathy had clinical bleeding 
while others had only a laboratory abnormality in coagulation parameters. 
70% of patients had anemia which can contribute to bleeding tendency by 
loss of laminar blood flow. Melena was the most common clinical bleed that 
we noted. 
 
Nearly half the study population exhibited thrombocytopenia and 
majority of them had their platelet counts between 80,000 and 1,00,000 cells 
/cu.mm which is less likely to cause major bleeding episode. This study 
confirms with previous studies that thrombocytopenia is the most common 
coagulation abnormality.  
 
Antithrombotic drugs were given only  to 6 patients in our study out of 
which 4 had clinical bleeding  thus emphasizing that antithrombotic drugs 
can create trouble when a critical care patient is planned for an invasive 
procedure. 
 
Only 3 out of 50 and 10 out of 50 patients had PT and aPTT 
prolongation respectively. Only 2 patients had prolongation of both PT and 
aPTT. This shows that abnormal PT, aPTT are not so common in ICU 
patients. 
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Only one patient had thrombocytopenia along with prolonged PT and 
aPTT who had DIC secondary to Sepsis. Such patients show dismal outcome. 
 
Nearly 86 % had D dimer positivity. But only the patient with 
thrombocytopenia and prolongd PT and aPTT was considered to have DIC. 
In other patients D dimer would have elevated non specifically in fibrinolytic 
conditions like liver disease, inflammation, pregnancy, trauma. 
 
Fibrinogen was not low in any of the patient. Instead we had elevated 
fibrinogen in 30 % of study population  which shows that fibrinogen can be 
elevated in conditions like chronic inflammatory states like atherosclerosis, 
sepsis and pregnancy. 
 
D dimer and Fibrinogen should be interpret only with other 
coagulation parameters. In our study only one patient has significant D dimer 
positivity who developed DIC secondary to sepsis. 
 
Regarding the etiology behind the coagulopathy sepsis was found to be 
the leading cause for coagulopahties which goes along  with previous studies 
done in critical care patients. 
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Renal failure and liver failure are next in line to cause coagulopathy. 
Use of antithrombotics is also a significant cause of bleeding tendency in our 
study. We didn’t encounter any case of immune mediated thrombocytopenia 
like TTP which requires prompt recognition . 
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CONCLUSION 
 
The inferences that this study brought : 
 
1. Coagulopathy is very common in critical care patients  
2. Thrombocytopenia is the commonest abnormality in hemostatic 
workup. 
3. Sepsis is the major cause for abnormal coagulation which can lead 
to DIC in critical care patients 
4. Use of antithrombotic drugs in critical care patients can be 
troublesome when an invasive procedure is planned. 
 
A rationale approach must be developed in treating critical care 
patients with abnormal coagulation parameters. Too much aggressive 
transfusions can do more harm than good. A good clinical judgement is 
required along with the current knowledge for treating such patients. 
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS USED IN THE TEXT 
 
AIDP  - Acute Inflammatory Demyelinating  
   Polyradiculopathy 
AKI  -  Acute Kidney Injury 
APC  -  Activated Protein C 
APLA -  Anti Phospholipid Antibody syndrome 
aPTT  -  activated Partial Thromboplastin Time 
BUN  -  Blood Urea Nitrogen 
COPD  - Chronic Obstructive Pulmonary Disease 
CKD  - Chronic Kidney Disease 
DCLD -  Decompensated Chronic Liver Disease 
DIC  -  Disseminated Intravascular Coagulation 
DITP  -  Drug Induced Thrombocytopenic Purpura 
DVT  -  Deep Venous Thrombosis 
EDTA -  Ethylene Diamine Tetraacetic Acid  
FDP  -  Fibrin Degradation Product 
FEU  -  Fibrinogen Equivalent Unit 
FFP  -  Fresh Frozen Plasma 
HELLP -  Hemolysis Elevated Liver enzymes Low  
Platelet count 
HIT  -  Heparin Induced Thrombocytopenia 
HUS  - Hemolytic Uremic Syndrome 
ICU  -  Intensive Care Unit 
 INR  -  International Normalized Ratio 
ITP  -  Idiopathic Thrombocytopenic Purpura 
LDH  -  Lactate DeHydrogenase 
MELD -  Model for End stage Liver Disease 
PF4  -  Platelet Factor 4 
SLE  -  Systemic Lupus Erythematosus  
TMA  -  Thrombotic Micro Angiopathies 
TRALI -  Transfusion Related Acute Lung Injury 
TTP  -  Thrombotic Thrombocytopenic Purpura 
VWF  -  Von Willebrand Factor. 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
PROFORMA 
LABORATORY EVALUATION OF BLEEDING DIATHESIS IN 
MEDICAL ICU PATIENTS 
 
Name:                Age:                   Sex: 
  
Patient ID:     Contact number:                          
Occupation: 
 
Presenting complaints : 
 
Duration of illness :    duration of stay in IMCU: 
 
 
Primary diagnosis: 
 
Examination findings : 
 
General examination :      vital signs: 
 
 
CVS:     RS:   P/A:                CNS: 
 
If there is clinical bleeding mention the site. 
 INVESTIGATIONS  
 
1. Complete Blood Count: 
Hb:   TC:   DC: P L E M 
ESR:   PCV:   Platelet: 
 
2. Renal Function Tests: 
Blood Urea:   Sr.Creatinine:   
Sr. Na:    Sr. K: 
 
3.Liver function tests 
Total bilirubin :   AST:   Total protein: 
Direct bilirubin :   ALT:   S.Albumin: 
Indirect bilirubin   ALK:   
 
 
 
 
4.Hemostasis profile: 
PT: test    aPTT: test   INR: 
 control                       control                            
 
D-dimer:    fibrinogen :   platelet: 
Peripheral smear: 
 
Specific investigations if any  : 
 
Antithrombotic drug usage: 
 
If yes mention the drug, dosage and duration and indication : 
  
  
  
 
                      TURNITIN – PLAGIARISM SCREEN SHOT 
 
 
              
   
  
 
 
 
INFORMATION SHEET 
 
 
 
• We are conducting a study on “LABORATORY EVALUATION OF 
BLEEDING DIATHESIS IN MEDICAL ICU PATIENTS” among patients 
admitted in Medical ICU at the Government General Hospital, Chennai and for 
that your sample may be valuable to us.
 
 
 
• The purpose of this study is to diagnose the bleeding diathesis that commonly 
occur  in critically ill medical ICU patients.  
 
• We are selecting certain cases and if your specimen is found eligible, we 
may be using your 4ml of blood sample to be collected in sodium citrate tube to 
perform the following tests namely platelet count & peripheral smear, PT, aPTT, 
D-dimer and Fibrinogen. These tests in any way do not affect your final report or 
management. 
 
• The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
• The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
 
 
Signature of investigator     
 
Date                                                                Signature of participant 
 
 
 
 
 INFORMATION CONSENT FORM 
 
Study Title : LABORATORY EVALUATION OF BLEEDING 
DIATHESIS IN MEDICAL ICU PATIENTS 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Name :  
Age/Sex :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to me in 
my own language ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study. ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological and biochemical tests. ❏ 
 
Signature/thumb impression    Signature of Investigator 
 
Patient’s Name and Address:    Study Investigator’s Name: 
 
Dr. M.SATHISH  KUMAR 
   
MASTER CHART 
Name Age Sex primary diagnosis 
duration 
of stay in 
IMCU 
Clinical 
bleeding 
Prabavathy  52 F Bronchiectasis 45 days nil 
Suresh babu  32 M DCLD 5 days yes 
Vedhiammal  40 F Sepsis 7 days yes 
Chitra  52 F AIDP  14 days no 
Renuga  14 F Viral encephalitis 10 days yes 
Kalaivani  23 F Sepsis post partum 4 days yes 
Srinivasan  39 M Pontine infarct  10 days nil 
Rayadu  49 M COPD 12 days nil 
Punniyakodi  60 M Meningoencephalitis 7 days nil 
Savithri  61 F Carcinoma larynx 33 days nil 
Rukmani  65 F Carcinoma breast  14 days yes 
Vinoth Kanna 45 M DCLD 5 days yes 
Ganesan  50 M Sepsis 7 days yes 
Ayapan  67 M CKD,Stroke 10 days nil 
Narayanan  35 M AIDP 5 days nil 
Saranya  21 F Meningoencephalitis  5 days nil 
Chellamuthu  35 M Heart failure 3 days nil 
Duraisamy  61 M Stroke (ischemic) 8 days yes 
Mala  38 F Ppneumonia,  3 days nil 
Sambasivam  50 M Mucormycosis  14 days nil 
Vasudevan  68 M Heart failure 13 days nil 
Jayaraman  78 M Stroke  6 days yes 
Krishnan  55 M Unknown primary  14 days yes 
Anjali  38 F Myasthenia gravis 7 days nil 
Sundaram  44 M DCLD 5 days yes 
Divya Bharathi  14 F Meningoencephalitis  7 days nil 
  
Loganathan  58 M AIDP 12 days nil 
Balan 66 M COPD 20 days nil 
Jai Ganesh  18 M CIDP 141 days yes 
Ramesh  30 M Stroke 7 days nil 
Thirupathy  65 M Status Epilepticus 5 days nil 
Nivedhitha 22 F Meningoencephalitis  6 days nil 
Priya 18 F Dengue hemorrhagic fever 4 days yes 
Kumar  47 M Stroke  24 days yes 
Rajamanickam  48 M Status Epilepticus 10 days nil 
Sadhana  13 F AIDP 3 days nil 
Dhanalakshmi 56 F Carcinoma cervix, CKD 7 days nil 
Krishnamoorthy  55 M TB meningitis 38 days nil 
Purushothaman  13 M status epilepticus 3 days nil 
Ram Kumar 20 M AIDP 6 days nil 
Pooovarasan 13 M RHD AR MR seizure 6 days nil 
Settu  50 M Massive infarct CVA 17 days nil 
Meena 28 F Eclampsia 6 days yes 
Chellaiah 65 M DCLD 7 days yes 
Annammal  50 F CKD, pulmonary edema 3 days nil 
Raju  34 M AIDP 28 days nil 
Kannagi  41 F MCTD 14 days nil 
Paranthaman  40 M Diabetic foot, Sepsis 8 days yes 
Bakkiyalakshmi  37 F POST PARTUM SEPSIS 45 days yes 
Santhanam  75 M Cerebellar hemorrhage  5 days nil 
 
 
 
 
 
 
 
   
Name site of bleed Hb peripheral 
smear 
platelet 
count 
PT INR aPTT 
prabavathy  nil 6 MCHC 1,75,000 12.5 0.96 23.3 
suresh babu  melena 8 MCHC 80,000 19.8 1.5 35.5 
vedhiammal  melena, rash 8.8 MCHC 47,000 13.1 1 30.9 
chitra  nil 9.8 MCHC 1,50,000 13.4 1.01 30.2 
renuga  melena  9.4 MCHC 80,000 12.8 0.98 16.2 
kalaivani  menorrhagia 7.5 MCHC 36,000 25 1.9 42 
srinivasan  nil 11.3 MCHC 3,36,000 13.5 1.03 22.7 
rayadu  nil 10.5 MCHC 80,000 13.8 1.05 25 
punniyakodi  nil 12.5 normal study 1,26,000 13.2 1 26 
savithri  nil  11.2 MCHC 1,64,000 13.5 1 24.4 
rukmani  melena 8.5 MCHC 70,000 13.2 1.02 29.2 
vinoth kanna oral cavity bleed 8.2 MCHC 68,000 26 2.1 40 
ganesan  skin bleed 11 MCHC 45,000 13.1 1.05 39.4 
ayapan  nil 7.8 MCHC 82,000 13.2 1 29.4 
narayanan  nil 13.5 normal study 2,25,000 14.2 1.08 24.6 
saranya  nil  10.3 MCHC 1,67,000 13.8 1.05 21.6 
chellamuthu  nil 10.5 MCHC 1,05,000 28 2.13 34 
duraisamy  melena  8 MCHC 1,24,000 19.7 1.49 30.5 
mala  nil 10.2 MCHC 72,000 14.4 1.09 31.5 
sambasivam  nil 8.5 MCHC 88,000 14.1 1.07 46.5 
vasudevan  nil 11.5 MCHC 1,08,000 14.2 1.08 30.2 
jayaraman  melena 12.5 normal study 98,000 13.5 1.02 32.4 
krishnan  melena  6.7 MCHC 1,52,000 33 2.45 67 
anjali  nil 11.2 MCHC 1,89,000 14.1 1.07 29 
 sundaram  hemetemesis 7.4 MCHC 58,000 20.1 1.5 40 
divya bharathi  nil 12.5 normal study 4,06,000 13.6 1.04 25.5 
loganathan  nil 13.5 normal study 1,89,000 14.1 1.07 32.1 
balan nil 13 normal study 2,25,000 13.5 1.02 26.1 
  
  
jai ganesh  melena  10.2 MCHC 98,000 14.2 1.08 27.4 
ramesh  nil 13.5 normal study 1,24,000 15.4 1.17 79.8 
thirupathy  nil 10.4 MCHC 2,60,000 15.2 1.16 21.9 
nivedhitha nil 12.5 normal study  87,000 14.5 1.1 22.5 
priya hematuria,epistaxis 10.5 MCHC 18,000 14 1.06 26.2 
kumar  melena  12.8 normal study  1,06,000 13.1 1 23.2 
rajamanickam  nil 12.4 normal study  1,45,000 15.1 1.15 31.2 
sadhana  nil 11 MCHC 96000 14 1.07 28.9 
dhanalakshmi nil 7.5 MCHC 1,10,000 14 1.07 26 
krishnamoorthy  nil 11.2 MCHC 1,09,000 15.2 1.16 30.5 
purushothaman  nil 10 MCHC 2,13,000 14 1.07 36.5 
ram kumar nil 13 normal study 2,98,000 13.2 1 24.8 
pooovarasan nil 12.2 normal study  2,32,000 12.6 0.96 29.3 
settu  nil 12.5 normal study  2,78,000 12.8 0.97 32 
meena melena  10.2 MCHC 84,000 15.2 1.16 32 
chellaiah melena  10.8 MCHC 80,000 15 1.14 40.7 
annammal  nil 7.5 MCHC 89,000 14.2 1.08 30.4 
raju  nil 13.5 normal study 2,45,000 13.1 1 22.4 
kannagi  nil 6.9 MCHC 54,000 13 0.99 28.2 
paranthaman  local site 9.8 MCHC 85,000 15.6 1.19 34 
bakkiyalakshmi  hematuria  8.8 MCHC 68,000 11.7 0.9 18.5 
santhanam  nil 10.2 MCHC 1,02,000 15.2 1.16 31.5 
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Prabavathy  1.5 501 no 23 0.6 31/28 1 
Suresh babu  4.3 202 no 36 1.2 60/32 3.2 
Vedhiammal  6.56 640 no 53.5 1.77 76/35 1.5 
Chitra  0.53 258 no 26 0.85 26/23 0.8 
Renuga  6.66 366 no 26 0.9 42/28 0.7 
Kalaivani  10.52 202 no 48 2.2 124/98 3.2 
Srinivasan  2.46 440 no 41 1 46/38 0.9 
Rayadu  1.8 220 no 30 1.4 44/32 1.2 
Punniyakodi  1.98 226 no 32 1.5 48/28 1.1 
Savithri  5.54 525 no 34 1.4 159/72 0.8 
Rukmani  6.54 302 no 28 1.2 98/64 2.1 
Vinoth kanna 5.68 248 no 68 2.5 78/36 4.2 
Ganesan  5.01 468 no 114 5.7 70/31 2.4 
Ayapan  1.4 235 no 98 4.8 56/24 0.8 
Narayanan  0.48 408 no 28 1.1 48/22 0.9 
Saranya  1.3 318 no 26 0.7 18/24 0.9 
Chellamuthu  2.25 314 acitrom 30 1.2 48/26 0.8 
Duraisamy  8.81 268 aspirin 158 4.6 122/92 0.8 
Mala  3.54 246 no 102 1.8 126/84 1.8 
Sambasivam  0.51 298 Heparin 113 3.1 18/15 0.8 
Vasudevan  1.8 308 aspirin 45 1.5 68/44 1.2 
Jayaraman  4.68 298 no 44 1.6 48/38 1.1 
Krishnan  1.98 810 heparin 97.2 1.92 28/25 0.6 
Anjali  0.64 424 no 38 1.2 26/19 0.8 
 Sundaram  2.84 324 no 42 1.8 68/42 2.5 
Divya bharathi  0.92 250 no 38 1.3 54/42 0.9 
  
 
 
 
 
Loganathan  0.86 354 no 45 1.2 35/22 0.8 
Balan 1.54 412 no 35 1.1 45/32 0.8 
Jai ganesh  1.76 314 no 24 0.7 27/161 0.9 
Ramesh  2.47 374 heparin 28 1.2 58/29 1.2 
Thirupathy  4.89 366 no 36 1.3 65/79 0.9 
Nivedhitha 0.46 424 no 22 0.8 114/86 1.1 
Priya 1.42 362 no 26 1.2 48/32 1.3 
Kumar  6.22 399 no 29 0.8 50/74 1 
Rajamanickam  3.36 392 no 39 1.4 89/65 1.2 
Sadhana  0.58 237 no 26 0.9 236/289 1 
Dhanalakshmi 1.56 308 no 98 5.5 154/122 1.5 
Krishnamoorthy  1.65 252 no 35 1.4 178/122 1.6 
Purushothaman  0.6 289 no 32 1 65/77 1.4 
Ram kumar 0.76 384 no 22 0.8 22/18 0.8 
Pooovarasan 0.56 354 no 22 0.8 38/34 0.8 
Settu  6.88 324 no 40 1.5 56/34 0.9 
Meena 4.68 282 no 28 1.2 88/68 1.4 
Chellaiah 6.4 309 no 62 1.8 36/31 4.1 
Annammal  3.89 238 no 108 6.7 78/64 1.2 
Raju  0.7 298 no 32 1.1 38/24 0.8 
Kannagi  4.31 490 no 84 0.8 34/27 1.2 
Paranthaman  2.25 246 no 82 2.4 112/88 2.6 
Bakkiyalakshmi  19.6 309 no 62 3.2 45/33 0.7 
Santhanam  5.64 423 no 32 1.2 35/24 0.8 
